The addition of anti-VEGF agents to chemotherapy significantly improve the OS of advanced GC patients when compared with chemotherapy alone.[18] But there is still no conclusive agreement on how to combine anti-angiogenic agents with other regimens to get prime effects. The gene discussed is VEGFA; the disease is gastric cancer.